TMCI logo

Treace Medical Concepts, Inc. Stock Price

NasdaqGS:TMCI Community·US$86.3m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

TMCI Share Price Performance

US$1.41
-6.91 (-83.05%)
US$3.85
Fair Value
US$1.41
-6.91 (-83.05%)
63.4% undervalued intrinsic discount
US$3.85
Fair Value
Price US$1.41
AnalystConsensusTarget US$3.85
AnalystHighTarget US$7.00
AnalystLowTarget US$4.00

TMCI Community Narratives

AnalystConsensusTarget·
Fair Value US$3.85 63.4% undervalued intrinsic discount

Minimally Invasive Bunion Solutions Will Broaden Market Penetration

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystHighTarget·
Fair Value US$7 79.9% undervalued intrinsic discount

Aging Population And Obesity Will Transform Foot Surgery

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystLowTarget·
Fair Value US$4 64.8% undervalued intrinsic discount

Elective Bunion Procedure Deferrals Will Pressure Margins Yet Long-Term Demand Will Ultimately Endure

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$3.85
63.4% undervalued intrinsic discount
Profit Margin
13.36%
Future PE
11.38x
Price in 2029
US$5.03
US$4
64.8% undervalued intrinsic discount
Profit Margin
12.91%
Future PE
12.22x
Price in 2028
US$5.12

Trending Discussion

Updated Narratives

TMCI logo

TMCI: New Product Mix And 2026 Outlook Will Support Future Upside

Fair Value: US$7 79.9% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
TMCI logo

TMCI: New Product Rollouts And 2026 Guidance Will Support Future Upside

Fair Value: US$3.85 63.4% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
TMCI logo

Elective Bunion Procedure Deferrals Will Pressure Margins Yet Long-Term Demand Will Ultimately Endure

Fair Value: US$4 64.8% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet and fair value.

3 Risks
1 Reward

Treace Medical Concepts, Inc. Key Details

US$212.7m

Revenue

US$42.9m

Cost of Revenue

US$169.8m

Gross Profit

US$228.8m

Other Expenses

-US$59.0m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-0.92
79.81%
-27.74%
65.6%
View Full Analysis

About TMCI

Founded
2013
Employees
450
CEO
John Treace
WebsiteView website
www.treace.com

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

Recent TMCI News & Updates

Recent updates

No updates